[1]肖 扬,李国政,刘 莹.基于临床试验信息分析冠心病心绞痛中药新药研发特点和趋势[J].医学信息,2021,34(09):23-27.[doi:10.3969/j.issn.1006-1959.2021.09.006]
　XIAO Yang,LI Guo-zheng,LIU Ying.Analysis of the Characteristics and Trends of New Chinese Medicines for Coronary Heart Disease and Angina Pectoris Based on Clinical Trial Information[J].Medical Information,2021,34(09):23-27.[doi:10.3969/j.issn.1006-1959.2021.09.006]
点击复制

基于临床试验信息分析冠心病心绞痛中药新药研发特点和趋势()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年09期
页码:
23-27
栏目:
出版日期:
2021-05-01

文章信息/Info

Title:
Analysis of the Characteristics and Trends of New Chinese Medicines for Coronary Heart Disease and Angina Pectoris Based on Clinical Trial Information
文章编号:
1006-1959（2021）09-0023-05
作者:
肖 扬; 李国政; 刘 莹
（天津中医药大学第二附属医院药学部1，中医经典病房2，天津 300000）
Author(s):
XIAO Yang; LI Guo-zheng; LIU Ying
(Department of Pharmacy1,Classic Ward of Traditional Chinese Medicine2,the Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300000,China)
关键词:
冠心病; 心绞痛; 中药
Keywords:
Coronary heart disease; Angina pectoris; Chinese medicine
分类号:
R541
DOI:
10.3969/j.issn.1006-1959.2021.09.006
文献标志码:
A
摘要:
目的 分析药物临床试验登记与信息公示平台（CDE）登记的中药治疗冠心病心绞痛的临床试验，为今后治疗冠心病心绞痛中成药的研发与临床试验设计提供参考。方法 于2020年10月1日，在国家药品监督管理局药品审评中心的CDE平台中提取冠心病心绞痛中药研发的相关临床试验，对其基本信息、人群特征、试验设计和疗效评价进行分析，总结该领域中药新药研发特点和趋势。结果 截止2020年10月CDE平台共登记53项冠心病心绞痛临床试验，涉及40个品种；研究药物剂型包括注射液、胶囊、片剂、滴丸和颗粒，分别有10个、9个、11个、8个和2个品种；研究阶段包括Ⅰ期15项、Ⅱ期26项、Ⅲ期10项和Ⅳ期2项；中医证型有13个，其中以心血瘀阻证和气虚血瘀证研究最多，分别有8个和7个；有14个研究进行剂量探索；试验疗程1~12周，其中疗程是8周的最多；评价指标以心绞痛症状相关指标最多，有37个项目。结论 目前治疗冠心病心绞痛的中成药种类繁多，但纳入人群、评价指标等方面重复性较高；从研究设计看，很难突出药物作用特点。期望今后在以临床价值为导向的研发理念下，通过合理的临床设计与疗效评价，体现中药的临床价值和优势。
Abstract:
Objective To analyze the clinical trials of traditional Chinese medicines registered on the drug clinical trial registration and information disclosure platform (CDE) for the treatment of coronary heart disease angina pectoris, and to provide references for the future development and clinical trial design of Chinese patent medicines for the treatment of coronary heart disease angina pectoris.Methods On October 1, 2020, the CDE platform of the Drug Evaluation Center of the National Medical Products Administration extracted relevant clinical trials for the development of Chinese medicine for coronary heart disease and angina pectoris, and analyzed its basic information, population characteristics,trial design and efficacy evaluation.Summarize the characteristics and trends of new Chinese medicine research and development in this field.Results As of October 2020, a total of 53 coronary heart disease angina pectoris clinical trials were registered on the CDE platform, involving 40 varieties;The research drug dosage forms included injections, capsules, tablets, dripping pills and granules, with 10, 9, 11, 8 and 2 varieties respectively;The research phase included 15 items in phase I, 26 items in phase II, 10 items in phase Ⅲ and 2 items in phase IV;There were 13 TCM syndrome types, among which the heart and blood stasis syndrome and the qi deficiency and blood stasis syndrome were the most studied, with 8 and 7 respectively;There were 14 studies to explore the dose; the trial course of treatment was 1 to 12 weeks, of which the treatment course was 8 weeks the most; the evaluation index was the most relevant index of angina pectoris, with 37 items.Conclusion At present, there are many kinds of Chinese patent medicines for the treatment of angina pectoris of coronary heart disease, but the inclusion population and evaluation indicators are highly reproducible;From the perspective of research design, it is difficult to highlight the characteristics of drug action. It is hoped that in the future, under the clinical value-oriented research and development concept, the clinical value and advantages of traditional Chinese medicine can be reflected through reasonable clinical design and efficacy evaluation.

参考文献/References:

[1]仇娜.益气通络,活血化痰中药汤剂治疗冠心病心律失常的临床疗效分析[J].中国现代药物应用,2020,14(24):232-234. [2]中华医学会心血管病学分会介入心脏病学组,中华医学会心血管病学分会动脉粥样硬化与冠心病学组,中国医师协会心血管内科医师分会血栓防治专业委员会, 等.稳定性冠心病诊断与治疗指南[J].中华心血管病杂志,2018,46(9):680-694. [3]王阶,陈光.冠心病稳定型心绞痛中医诊疗专家共识[J].中医杂志,2018,59(5):447-450. [4]李耿,郭宇博,李文姗,等.中药大品种科技竞争力报告(2019版)概要[J].中国现代中药,2020,22(1):1-20. [5]娜荣华,张钢铁.对186种治疗冠心病和心绞痛中成药的分析[J].中国现代药物应用,2013,7(12):143-145. [6]于成瑶,李连达.1985-2003年治疗冠心病的中药新药研制情况分析[J].中国新药杂志,2005(11):122-123. [7]程龙.《中药、天然药物治疗冠心病心绞痛临床研究指导原则》解读[J].中国执业药师,2012,9(3):3-6. [8]林飞,王阶,郭丽丽, 等.《中华人民共和国药典》收载治疗冠心病心绞痛中成药配伍规律分析[J].中医杂志,2013,54(18):1596-1599. [9]柳正植,崔英子,杨薇,等.冠心病稳定型心绞痛中药临床试验方案设计的变化趋势[J].长春中医药大学学报,2016,32(1):187-190. [10]毕颖斐,王贤良,毛静远,等.基于临床流行病学调查的冠心病心绞痛中医证候诊断建议[J].中医杂志,2018,59(22):1977-1980. [11]焦岩,董波,李国信,等.对中药治疗冠心病心绞痛临床研究纳入标准的思考[J].中西医结合心脑血管病杂志,2017,15(7):879-881. [12]焦岩,王东海,李国信,等.中药新药Ⅱ期、Ⅲ期冠心病心绞痛临床试验中依从性分析[J].中西医结合心脑血管病杂志,2016,14(8):844-846. [13]中华中医药学会心血管病分会.冠心病稳定型心绞痛中医诊疗指南[J].中医杂志,2019,60(21):1880-1890. [14]魏鹏路,顾浩,关双,等.已上市中成药治疗不同证候冠心病心绞痛的核心处方挖掘[J].中国中药杂志,2019,44(5):1041-1047. [15]张洪源,刘光辉,王洋,等.基于数据挖掘和整合药理学对中药桃仁治疗冠心病的分子机制探讨[J].中华中医药学刊,2019,37(8):1917-1920,后插11. [16]王可仪,金鑫瑶,王虎城,等.中医药治疗不稳定型心绞痛临床研究指标分析[J].天津中医药,2020,37(10):1150-1155. [17]荣鸽璇,李昕玲,谭弘,等.大柴胡汤加减对冠心病不稳定型绞痛的多中心、随机、双盲对照临床研究[J].世界中医药,2019,14(4):882-886. [18]柳小春,刘丽仙,林能明.养心汤联合常规西药治疗心气虚弱型冠心病不稳定性心绞痛临床研究[J].新中医,2019,51(3):90-93. [19]王东海,董波,李国信.中药新药Ⅱ、Ⅲ期冠心病心绞痛临床试验的风险与对策[J].辽宁中医杂志,2015,42(12):61-63. [20]程龙.冠心病心绞痛口服给药临床研究申请存在问题分析及建议[J].中国执业药师,2012,9(5):40-42.

相似文献/References:

[1]张文魁.硝酸甘油联合阿司匹林治疗心绞痛的临床效果观察[J].医学信息,2018,31(02):119.[doi:10.3969/j.issn.1006-1959.2018.02.043]
　ZHANG Wen-kui.Clinical Effect of Nitroglycerin Combined with Aspirin in the Treatment of Angina Pectoris[J].Medical Information,2018,31(09):119.[doi:10.3969/j.issn.1006-1959.2018.02.043]
[2]袁 帅,邢晓博,李 晓,等.MTHFR基因多态性与中年男性冠状动脉病变程度的相关研究[J].医学信息,2018,31(03):67.[doi:10.3969/j.issn.1006-1959.2018.03.021]
　YUAN Shuai,XING Xiao-bo,LI Xiao,et al.Association of MTHFR Gene Polymorphism with Coronary Artery Lesions in Middle-aged Men[J].Medical Information,2018,31(09):67.[doi:10.3969/j.issn.1006-1959.2018.03.021]
[3]张挺挺.经股和桡动脉介入治疗冠心病的临床疗效对比[J].医学信息,2018,31(03):114.[doi:10.3969/j.issn.1006-1959.2018.03.038]
　ZHANG Ting-ting.Comparison of Clinical Effects of Interventional Treatment of Coronary Heart Disease by Femoral and Radial Artery[J].Medical Information,2018,31(09):114.[doi:10.3969/j.issn.1006-1959.2018.03.038]
[4]迮艳华.稳心颗粒联合美托洛尔治疗冠心病心律失常的疗效分析[J].医学信息,2018,31(03):139.[doi:10.3969/j.issn.1006-1959.2018.03.049]
　ZE Yan-hua.Therapeutic Effect of Wenxin Granule Combined with Metoprolol on Arrhythmia of Coronary Heart Disease[J].Medical Information,2018,31(09):139.[doi:10.3969/j.issn.1006-1959.2018.03.049]
[5]向明明,赵晓辉.黑龙江省东部地区汉族人群冠心病的危险因素研究[J].医学信息,2018,31(07):122.[doi:10.3969/j.issn.1006-1959.2018.07.041]
　XIANG Ming-ming,ZHAO Xiao-hui.Study on Risk Factors of Coronary Heart Disease in Han Nationality Population in Eastern Heilongjiang Province[J].Medical Information,2018,31(09):122.[doi:10.3969/j.issn.1006-1959.2018.07.041]
[6]王 坤,张永春.血清胆红素水平、单核细胞数、红细胞分布宽度与 冠状动脉病变程度的关系[J].医学信息,2018,31(08):53.[doi:10.3969/j.issn.1006-1959.2018.08.017]
　WANG Kun,ZHANG Yong-chun.Relationship between Serum Bilirubin Level,Monocyte Count,Red Blood Cell Distribution Width and Severity of Coronary Artery Disease[J].Medical Information,2018,31(09):53.[doi:10.3969/j.issn.1006-1959.2018.08.017]
[7]毛红岩.冠状动脉介入治疗冠心病的疗效及 对患者血清炎症因子的影响[J].医学信息,2018,31(10):77.[doi:10.3969/j.issn.1006-1959.2018.10.023]
　MAO Hong-yan.Effect of Coronary Intervention on Coronary Heart Disease and its Influence on Serum Inflammatory Factors[J].Medical Information,2018,31(09):77.[doi:10.3969/j.issn.1006-1959.2018.10.023]
[8]杨锦龙,刘 欢,吕秋菊,等.非糖尿病患者糖化血红蛋白和胰岛素抵抗与 冠状动脉病变程度的相关性研究[J].医学信息,2018,31(10):93.[doi:10.3969/j.issn.1006-1959.2018.10.028]
　YANG Jin-long,LIU Huan,LV Qiu-ju,et al.Correlation between Glycosylated Hemoglobin and Insulin Resistance and Severity of Coronary Artery Disease in Non-diabetic Patients[J].Medical Information,2018,31(09):93.[doi:10.3969/j.issn.1006-1959.2018.10.028]
[9]李 铎,王建华.盐酸曲美他嗪片辅助治疗对冠心病伴心力衰竭患者氧化应激、心肌功能的影响[J].医学信息,2018,31(10):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
　LI Duo,WANG Jian-hua.Effect of Trimetazidine Hydrochloride Tablets Adjuvant Therapy on Oxidative Stress and Myocardial Function in Patients with Coronary Heart Disease Complicated with Heart Failure[J].Medical Information,2018,31(09):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
[10]田跃雷.冠心病介入治疗后再狭窄的中西医防治[J].医学信息,2022,35(09):46.[doi:10.3969/j.issn.1006-1959.2022.09.011]
　TIAN Yue-lei.Prevention and Treatment of Restenosis After Percutaneous Coronary Intervention with Chinese and Western Medicine[J].Medical Information,2022,35(09):46.[doi:10.3969/j.issn.1006-1959.2022.09.011]
[11]张 旭.冠心病心绞痛患者进行护理干预的临床效果及 对护理质量影响研究[J].医学信息,2018,31(05):182.[doi:10.3969/j.issn.1006-1959.2018.05.068]
　ZHANG Xu.Clinical Effect of Nursing Intervention in Patients with Angina Pectoris of Coronary Heart Disease and its Influence on Nursing Quality[J].Medical Information,2018,31(09):182.[doi:10.3969/j.issn.1006-1959.2018.05.068]
[12]宫丽萍.血府逐瘀汤加减治疗气滞血瘀型冠心病心绞痛的疗效研究[J].医学信息,2018,31(12):145.[doi:10.3969/j.issn.1006-1959.2018.12.046]
　GONG Li-ping.Therapeutic Effect of Xuefu Zhuyu Decoction on Angina Pectoris with Qi Stagnation and Blood Stasis[J].Medical Information,2018,31(09):145.[doi:10.3969/j.issn.1006-1959.2018.12.046]
[13]杜 敏.冠心病患者血清小而密低密度脂蛋白胆固醇分析[J].医学信息,2019,32(12):172.[doi:10.3969/j.issn.1006-1959.2019.12.058]
　DU Min.Analysis of Serum Small,Dense Low-density Lipoprotein Cholesterol in Patients with Coronary Heart Disease[J].Medical Information,2019,32(09):172.[doi:10.3969/j.issn.1006-1959.2019.12.058]
[14]陈淑玲.临床护理路径对冠心病心绞痛患者生活质量的影响[J].医学信息,2021,34(19):178.[doi:10.3969/j.issn.1006-1959.2021.19.049]
　CHEN Shu-ling.Effect of Clinical Nursing Pathway on Quality of Life of Patients withAngina Pectoris of Coronary Heart Disease[J].Medical Information,2021,34(09):178.[doi:10.3969/j.issn.1006-1959.2021.19.049]
[15]朱周圆,刘 芳,李毅然.尼可地尔联合卡维地洛对冠心病心肌缺血患者心率及血压水平的影响[J].医学信息,2022,35(24):136.[doi:10.3969/j.issn.1006-1959.2022.24.028]
　ZHU Zhou-yuan,LIU Fang,LI Yi-ran.Effect of Nicorandil Combined with Carvedilol on Heart Rate and Blood Pressure in Patients with Coronary Heart Disease and Myocardial Ischemia[J].Medical Information,2022,35(09):136.[doi:10.3969/j.issn.1006-1959.2022.24.028]
[16]胡国梁,彭 冬,陈方圆.氯吡格雷联合阿司匹林肠溶片治疗冠心病心绞痛的效果及安全性分析[J].医学信息,2024,37(17):120.[doi:10.3969/j.issn.1006-1959.2024.17.025]
　HU Guo-liang,PENG Dong,CHEN Fang-yuan.Analysis of the Effect and Safety of Clopidogrel Combined with Aspirin Enteric-coated Tabletsin the Treatment of Angina Pectoris of Coronary Heart Disease[J].Medical Information,2024,37(09):120.[doi:10.3969/j.issn.1006-1959.2024.17.025]
[17]花世廷.硫酸氢氯吡格雷片与阿司匹林肠溶片治疗冠心病患者的疗效及对心功能的影响[J].医学信息,2024,37(18):112.[doi:10.3969/j.issn.1006-1959.2024.18.022]
　HUA Shi-ting.Efficacy of Clopidogrel Hydrogen Sulphate Tablets Combined with Aspirin Enteric Coated Tablets in the Treatment of Patients with Coronary Heart Disease and its Effect on Cardiac Function[J].Medical Information,2024,37(09):112.[doi:10.3969/j.issn.1006-1959.2024.18.022]
[18]邓嘉奇,曾祥斌,刘 琳,等.阿托伐他汀联合曲美他嗪在冠心病治疗中的临床疗效及对预后的影响[J].医学信息,2024,37(20):96.[doi:10.3969/j.issn.1006-1959.2024.20.018]
　DENG Jiaqi,ZENG Xiangbin,LIU Lin,et al.Clinical Efficacy of Atorvastatin Combined with Trimetazidine in the Treatment of Coronary Heart Disease and its Effect on Prognosis[J].Medical Information,2024,37(09):96.[doi:10.3969/j.issn.1006-1959.2024.20.018]
[19]吴有英.心电图检查联合临床特征诊断冠心病心绞痛的价值[J].医学信息,2024,37(23):151.[doi:10.3969/j.issn.1006-1959.2024.23.036]
　WU Youying.Value of Electrocardiogram Combined with Clinical Features in the Diagnosis of Angina Pectoris of Coronary Heart Disease[J].Medical Information,2024,37(09):151.[doi:10.3969/j.issn.1006-1959.2024.23.036]

更新日期/Last Update: 1900-01-01